射频消融与手术再切除治疗复发性肝癌的比较

目的: 比较射频消融和手术再切除治疗原发性肝癌手术切除后复发癌患者的临床疗效。 方法: 分析比较2002年5月至2007年10月76例原发性肝癌手术切除后复发癌患者射频消融(n=45)和手术再切除(n=31)的临床疗效,引入COX比例风险模型初步分析探讨影响再复发和复发后患者生存期的可能因素。 结果: 消融组与再手术组比较,肿瘤完全清除率分别为88.9%和100%(P=0.147),1、2、3、5年复发率分别为45.2%、71.6%、80.1%、86.7%和39.6%、60.9%、77.6%、83.2%(P=0.711),1、2、3、5年复发后生存率分别为81.8%、60.1%、40.3%、24.2%和82.9%、64.7%、46.4%、34.8%(P=0.599)。复发间期(复发癌距初次手术切除的时间)及复发癌结节个数是影响再手术切除和消融治疗后再复发的危险因素(P=0.035,P=0.005),复发癌结节个数及再复发时间是影响复发后患者生存期的危险因素(P=0.006,P=0.000)。消融组并发症的发生率为13.3%,再手术组为29.0%(P=0.091)。消融组患者无需输血而再手术组需输血的比率为35.5%(P=0.000)。住院时间消融组为7.0天±0.8天,较之再手术组21.9天±1.6天明显缩短(P=0.000)。 结论: 对于原发性肝癌切除术后复发癌患者射频消融术亦可以获得与手术再切除相当的长期生存率,而且具有微创、经济、重复性好的优势,适合于复发癌患者的治疗。     

老年肝癌患者的射频消融治疗

目的 比较射频消融治疗老年和非老年肝癌患者的临床疗效。方法回顾性分析比较2004年3月~2007年8月77例老年和非老年肝癌患者射频消融的治疗效果,年龄≥60岁者为老年组(n=31),＜60岁者为非老年组(n=46)。结果 老年组与非老年组比较,肿瘤完全清除率87.1％vs 82.6%(P=0.832),1~3年复发率分别为44.4％、59.8％、71.3％vs 56.4％、70.7％、78.1％(P=0.464)。1~3年生存率分别为89.6％、63.8％、35.9％vs 78.9％、46.6％、20.1％(P=0.114)。并发症的发生比率分别为29.0％vs 26.1％(P=0.776)。肿瘤个数、初治时是否复发及治疗后是否再复发是影响预后的危险因素,而年龄、肿瘤直径不是预后的影响因素。结论 对于老年肝癌患者PRFA治疗可以获得与非老年患者相当的长期生存率,而其微创、重复性好的优势更适合老年肝癌患者,尤其是复发癌患者。     

多电极射频消融治疗肝癌的现状与展望

多电极射频消融(RFA)治疗肝癌是较先进的一种姑息疗法，为微创治疗肝癌提供了一种新的有效方法。本文综述多电极射频消融治疗系统的组成、治疗原理、临床效果、适应证、并发症、技术难点及解决方案等。     

多电极射频消融治疗肝癌的现状与展望

多电极射频消融（RFA）治疗肝癌是较先进的一种姑息疗法，为微创治疗肝癌提供了一种新的有效方法。本文综述多电极射频消融治疗系统的组成，治疗原理，临床效果。适应证，并发症，技术难点及解决方案等。     

手术切除联合术中射频在多发性肝癌患者中的应用

目的：探讨手术切除联合术中射频消融（ radiofrequency ablation,RFA）治疗多发性肝癌（ hepatocellular carcinoma,HCC）的安全性及可行性。方法：2005年1月至2014年1月,我院收治多发性肝癌（≥2个）患者42例,术前通过彩超、增强CT、MRI共发现肿瘤病灶112个,术中超声新发现肿瘤9个。手术方式包括：半肝切除7例,右肝后叶切除2例,左肝外叶切除6例,不规则肝切除27例,共切除肿瘤病灶49个。RFA处理肿瘤病灶72个。术中常规施行超声造影。结果：所有患者均成功完成手术。手术切除肿瘤时间14~45min（25.1±12.8）min。单个肿瘤病灶RFA时间9~37min（17.2±11.9）min,总RFA时间16~61min（36.4±19.2）min。总的手术时间73~189min（138.2±76.6）min。术中出血量80~1100ml（429.7±226.5）ml。无肝肾功能衰竭、胃肠及膈肌损伤等发生。术后7天开始抗病毒治疗（ HBV DNA≥5.00E＋2IU/ml）,术后1月行TACE。术后失访2例,40例随访时间为6~103月（49.2±31.8）月。对于复发病例采用再次手术切除、RFA、TACE等方法治疗。结论：手术切除联合RFA治疗多发性肝癌能最大限度保存正常肝脏组织,提高肝癌根治性切除率,有选择的实施安全可行。     

经皮射频消融与手术切除治疗小肝癌的疗效对比分析

目的探讨经皮射频消融(PRFA)与手术切除治疗小肝癌的临床疗效。方法收集120例小肝癌患者临床资料,按照不同的治疗方法,分为射频组以及手术组,各60例。射频组患者采取经皮射频消融术治疗,手术组患者实施手术切除治疗,随访3年,最后对比2组患者的生存率、复发率、并发症发生率等。结果观察组患者治疗后1年、2年、3年的生存率分别为96.67%、86.67%、63.33%,与对照组的95.00%、83.33%、61.67%差异不明显,无统计学意义(P>0.05);2组患者的肿瘤直径≤3 cm、肿瘤3~5 cm患者复发率对比,差异无统计学意义(P>0.05)。射频组患者并发症发生率为10.00%,明显低于手术组的25.00%,差异有统计学意义(P<0.05)。结论对直径≤5 cm的小肝癌PRFA治疗效果确切,近远期疗效与手术切除相近,且并发症发生率较低,可作为小肝癌的首选治疗手段。     

射频消融在肝癌治疗中的应用与研究进展

 射频消融 (radiofrequencyablation ,RFA)是近几年来兴起的一种新的局部治疗肝癌的方法。具有操作简便、创伤小、副作用及并发症少、疗程短和安全可靠的优点 ,引起临床工作者越来越多的重视。本文对RFA技术的基本原理、射频后组织病理改变、副作用及并发症、RFA面临的主要问题及提高RFA效果的研究作一综述。1　RFA基本原理RFA的原理是将射频电极插入组织内通过射频发生器发射 4 6 0 5 0 0kHz的射频电流 ,使组织带电粒子振荡摩擦产热而直接毁损病灶。热杀死细胞主要与以下几个方面有关 :①细胞膜损伤 ,包括细胞膜成分、膜通透性及流动性等改变导致细胞死亡 ;②溶酶体损伤 ,溶酶体内消化酶的释放引起细胞死亡 ;③与合成DNA、RND有关的蛋白质受损伤而间接引起细胞死亡。其生物学基础是 :热对乏氧细胞的敏感性与对足氧细胞的不同 ;低 pH值及营养不良环境能增加热对细胞的杀灭能力 ;细胞分裂周期中对射线抵抗的S期细胞对热敏感 ;肿瘤散热能力差[1] 。射频也使肿瘤组织微管系统完全破坏 ,直径小于 3mm的肝动脉、门静脉、及肝静脉发生栓塞 ,在肿瘤周围的血管组织形成一个反应带 ,使之不能向肿瘤...     

冷循环电极射频消融治疗肝脏恶性肿瘤

２００１年１２月至２００２年２月，应用冷循环电极射频消融治疗（RFA）２３例肝脏肿瘤，报告如下。１材料与方法１．１临床资料男１６例，女７例；年龄４４～７８岁，平均６１岁。全部病例均经手术或超声引导穿刺病理学确诊，共４３个结节，最大直径２．５０～１２．００cm，中位数为４．２５cm。原发性肝癌２０例（共３３个结节），转移性肝癌３例（共１０个结节），分别为结肠癌术后１０个月１例，直肠癌术后１５个月１例，胃平滑肌肉瘤术后３４个月１例。患者一般状态尚好，２例B超提示少量腹水。原发性肝癌２０例中肝功能ChildA级…     

多针双电极射频适形消融治疗肝癌16例报告

目的 探讨多针双电极射频适形消融治疗肝癌的原理和近期疗效。方法 采用多针双电极射频消融肝肿瘤16例,全部采用超声引导下经皮穿剌,单纯射频消融治疗15例,射频消融联合瘤内无水酒精注射术治疗1例。结果 全组有12例患者治疗1次后影像学检查见肿瘤完全消融,4例首次射频治疗后1个月影像学检查见肿瘤消融不完全,2例再次行射频消融后肿瘤完全消融。甲胎蛋白阳性者6例治疗后全部转为阴性。结论 多针双电极射频不仅能增大消融范围,而且可以根据肿瘤形态适形消融肿瘤,是1种新的有效射频消融技术。     

无水酒精注射联合射频消融治疗射频消融困难部位的肝癌

目的:探讨无水酒精注射联合射频消融治疗射频消融困难部位肝癌的疗效.方法:回顾性分析靠近结肠、胆囊、大中血管、膈肌等存在射频困难区肝癌患者31例,在采用射频治疗后残余病灶行无水酒精补充治疗,评价病灶坏死率及术后并发症.结果:31例患者的47个病灶当中共有33个病灶位于射频困难部位,肿瘤完全坏死率为72.7%(24/33).无腹腔内出血,胆囊穿孔,结肠穿孔等严重并发症出现.结论:射频困难部位的肝癌病灶采用射频补充无水酒精注射治疗效果良好,未见严重的射频或酒精注射相关并发症发生,可在肝癌的综合治疗中推广应用.     

多电极射频治疗42例小肝癌疗效观察

目的:探讨多电极射频疗法对小肝癌的治疗效果.方法:应用直径3.5cm多电极射频针在B超引导下经肋间或肋下经肝实质刺入肿瘤组织中.射频针的十根电极呈“伞形”分布,一次烧灼后形成直径3.5m～3.9cm,高度为1.2cm～1.5cm的半球形毁损区,重复多次直至将肿瘤区域完全覆盖.结果:42例患者行多电极射频治疗,23例AFP阳性患者,术后2月内全部转阴.病灶内动静脉血流频谱均消失,5例患者行肝动脉造影,也证实肿瘤内血供消失.术后3月复查,肿瘤均有所缩小,最大达1/2.所有患者均存活超过3个月.结论:多电极射频治疗将来可代替手术切除成为小肝癌治疗的首选方法.     

Short-term efficacy of precise hepatectomy and traditional hepatectomy for primary liver cancer: a systematic review and meta-analysis

BackgroundAs the base of hepatitis B patients has been increasing annually, it has developed into a high incidence source of primary liver cancer worldwide. The fatality rate of liver cancer is still relatively high. Among the many treatment methods, liver resection is the first-line treatment of primary liver cancer. Although precision hepatectomy has achieved rapid development in recent years, the understanding of its efficacy is still not completely clear. This study aimed to analyze and compare the safety and effectiveness of precision hepatectomy and traditional hepatectomy in the treatment of primary liver cancer.MethodsWe performed a literature search of the CNKI, Wanfang, Weipu.com, PubMed, Cochrane Library, Web of Science databases for studies on precision liver resection (precision group) and traditional liver resection (traditional group) for the treatment of primary liver cancer. Data including the operation time, intraoperative blood loss, hospital stay, postoperative complications, liver function, and survival rate were analyzed using RevMan 5.3 software to compare the differences in the effects of the two surgical procedures.ResultsTen articles were included in the study, involving a total of 1,969 patients, including 1,045 cases in the precision group and 924 cases in the traditional group. Meta-analysis results showed that compared with the traditional group, the precision group had a longer operation time [mean difference (MD) =8.01, P=0.004], and total bilirubin (TBiL; MD =–2.78, P=0.055) was similar. Meanwhile, the precision group exhibited advantages in terms of intraoperative blood loss (MD =–149.37, P=0.000), hospital stay (MD =–5.59, P=0.000), postoperative liver function indexes [aspartate aminotransferase (AST; MD =–11.61, P=0.000) and alanine aminotransferase (ALT; MD =–18.53, P=0.000)], postoperative complication rate [relative risk (RR) =0.51, P=0.000], and 1-year survival rate (RR =1.11, P=0.000).DiscussionThe application of precision surgery in the treatment of primary liver cancer can be a safe and effective method. It can minimize intraoperative blood loss, mitigate surgical risk, reduce postoperative complications, improve patient prognosis and quality of life, and provide better short-term curative effect and patient benefits.     

Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer

BACKGROUND: The prognosis of patients with liver metastasis from gastric cancer (LMGC) is dismal. The purpose of this study was to review our recent outcomes of hepatectomy for LMGC and to determine the suitable candidates for surgery. STUDY DESIGN: The outcomes of 37 patients with LMGC who underwent hepatectomy between 1990 and 2005 were assessed. No extrahepatic distant metastasis and feasibility of macroscopic curative resection were requisite indications for surgery. The prognostic values of clinicopathological factors were assessed by univariate and multivariate analyses. RESULTS: There was no in-hospital mortality. The median survival time and overall 5-year survival rate after hepatectomy of the patients with LMGC were 31 months and 11%, respectively. Intrahepatic recurrence following hepatectomy was found in 23 patients (62%). Variables independently associated with poor survival were bilobar metastasis (P = 0.002, CI = 1.9-16.3) and a maximum tumor diameter of >or= 4 cm (P = 0.006, CI = 1.4-7.7). The depth of the primary tumor and the timing of metastasis were not associated with survival. CONCLUSIONS: Surgical resection for LMGC may be indicated in patients with unilobar metastasis and/or tumors less than 4 cm in diameter. Synchronous metastasis is not a contraindication for hepatectomy.     

射频消融术和腹腔镜肝切除术治疗复发性肝癌的临床疗效及远期生存情况分析

目的探讨射频消融术(RFA)和腹腔镜肝切除术(LH)治疗复发性肝癌的临床疗效及远期生存情况。方法依据随机数字表法将58例复发性肝癌患者分为LH组(接受LH治疗)和RFA组(接受RFA治疗),每组29例。比较治疗前和治疗后4周两组患者的血清肝功能指标[总胆红素(TBIL)、天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)]和肿瘤标志物[癌胚抗原(CEA)、磷脂酰肌醇蛋白聚糖3(GPC3)、甲胎蛋白(AFP)]水平,比较两组患者术后并发症发生率及3年生存情况。结果治疗前,两组患者的血清TBIL、AST、ALT、CEA、GPC3、AFP水平比较,差异均无统计学意义(P﹥0.05)。治疗后4周,RFA组患者的血清ALT、AST水平均高于LH组,差异均有统计学意义(P﹤0.05)。LH组患者的并发症总发生率为20.69%,高于RFA组的3.45%,差异有统计学意义(P﹤0.05)。两组患者的3年无进展生存情况和总生存情况比较,差异均无统计学意义(P﹥0.05)。结论对于复发性肝癌,LH与RFA治疗具有相似的长期疗效,但RFA治疗的安全性较好。     

Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases

BACKGROUND: Results and indications of intra-operative radiofrequency (RF) ablation of liver metastases (LM) are not well defined in the literature. AIM: To appreciate the survival rate of patients with strictly unresectable LM (defined on technical but not oncological criteria) when undergoing liver resection plus RF, along with optimal systemic chemotherapy. PATIENTS AND METHODS: Sixty three patients with technically unresectable LM (either >5, or bilateral with no sparing of at least one sector of the liver, or with tumor proximity to central major vascular structures) were treated. Extrahepatic metastases were also resected in 27% of patients. All patients received perioperative chemotherapy. The median follow-up was 27.6 months (range: 15-74). RESULTS: There was no postoperative mortality and the morbidity rate was 27%. The 2-year overall survival rate of the 63 patients was 67% with a median survival of 36 months. The local recurrence rates were similar for the three types of local treatments: 7.1% for the 154 RF ablations, 7.2% for the 55 wedge resections, and 9% for the 44 segmental anatomic resections (P = 0.216). Hepatic recurrences occurred in 71% of patients. CONCLUSION: The combination of anatomic segmental and wedge resections, RF ablation, and optimal chemotherapy in patients with technically unresectable LM results in a median survival of 36 months.     

肝癌切除加免疫化疗对术后复发的影响

Ojbective To Study the effects of combined hepatectomy and immunochemotherapy on postoperative recurrence of primary liver cancer.Methods 121 caes were divided into four groups:operation only(OP group);combined operation and chemotherapy(OC group);combined operation and immunotherapy(OI group);combined operation and immunochemotherapy(OIC group).Chemotherapy was performed through hepatic arter or port vein,and the immunotherapy was used with LAK cell IL-2 and IFN-γ。Results Three-yeau recurrence rate in the four groups was 76.7%,55.6%,45.2% and 36.4%,respectively.The recurrence rate of OI group and OIC group was significantly lower than that of OP group.Conclusion Combined operation and immunochemotherapy in useful in preventing postoperative recurrence of primary liver cancer.     

原发性肝癌极量肝切除的确定

目的 探讨原发性肝癌(简称肝癌)患者行极量肝切除的指征和安全性。 方法 2000年11月～2002年10月行极量肝切除治疗原发性肝癌共33例,合并肝硬化者26例,分析评估肝癌极量肝切除的术前各项指标、术中处理和术后恢复情况。 结果 全组无手术死亡,术后并发症发生率为33.3％,经及时治疗后均顺利恢复。 结论 肝脏储备功能良好的肝癌患者,在保证切肝量不超过肝组织量的50％的基础上,尽可能多地保留肝组织,术后加强残肝功能保护,及时处理并发症,肝癌行极量肝切除仍然是安全的。     

精准外科时代3D可视化技术在肝癌切除术中的应用价值

目的探讨精准外科时代3D可视化技术在肝癌切除术中的应用价值。方法采用随机数字表法将100例原发性肝癌患者分为3D组和常规组,每组50例,3D组患者实施3D可视化技术辅助肝癌切除术,常规组患者实施常规肝癌切除术。比较两组患者的手术情况、肝功能指标[丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)水平]、肝功能损伤程度、术后并发症发生情况、术后1年生存及复发情况。结果3D组患者的术中出血量明显少于常规组,肝门阻断时间和手术时间均明显短于常规组,差异均有统计学意义(P﹤0.01)。两组患者的实际切除肝体积比较,差异无统计学意义(P﹥0.05)。术后第1天、第3天、第5天,3D组患者的ALT和AST水平均低于常规组,差异均有统计学意义(P﹤0.05)。3D组患者的肝功能损伤程度明显小于常规组,差异有统计学意义(P﹤0.01)。3D组患者的术后并发症总发生率为18.0%(9/50),明显低于常规组的56.0%(28/50),差异有统计学意义(P﹤0.01)。3D组患者的1年生存率高于常规组,1年复发率低于常规组,差异均有统计学意义(P﹤0.05)。结论精准外科时代3D可视化技术应用于肝癌切除术中能够有效减轻患者肝组织的损伤程度,减少术后并发症,延长患者的生存时间,具有良好的应用价值。